<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-7459</journal-id>
<journal-title><![CDATA[Horizonte sanitario]]></journal-title>
<abbrev-journal-title><![CDATA[Horiz. sanitario]]></abbrev-journal-title>
<issn>2007-7459</issn>
<publisher>
<publisher-name><![CDATA[Universidad Juárez Autónoma de Tabasco, División Académica de Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-74592022000300485</article-id>
<article-id pub-id-type="doi">10.19136/hs.a21n3.4721</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Análisis costo-efectividad de alternativas de tratamiento para osteoporosis en mujeres postmenopáusicas en México]]></article-title>
<article-title xml:lang="en"><![CDATA[Cost-effectiveness analysis of treatment alternatives for osteoporosis in postmenopausal women in Mexico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Flores-Silva]]></surname>
<given-names><![CDATA[Frida Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Diaz-Solis]]></surname>
<given-names><![CDATA[Sayra Melisa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arredondo&#8224;]]></surname>
<given-names><![CDATA[Armando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[Cuernavaca Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[Cuernavaca Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Salud Pública  ]]></institution>
<addr-line><![CDATA[Cuernavaca Morelos]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>21</volume>
<numero>3</numero>
<fpage>485</fpage>
<lpage>493</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-74592022000300485&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-74592022000300485&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-74592022000300485&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Identificar el tratamiento de osteoporosis más costo- efectivo en la prevención de fracturas de cadera en mujeres mexicanas postmenopáusicas sin seguridad social en el primer nivel de atención.  Material y Métodos: Se realizó un análisis de costo-efectividad para tres esquemas de tratamiento de osteoporosis seleccionados por sus diferentes vías de aplicación y dosificación. Los tratamientos se estimaron para el periodo de un año. Los costos de cada intervención se estimaron desde la perspectiva del proveedor y se tomaron los precios del mercado mexicano disponibles en julio de 2021. La efectividad se determinó a partir de estudios previos sobre el efecto de los medicamentos sobre la fractura de cadera. Se determinó el coeficiente costo-efectividad de cada tratamiento.  Resultados: La intervención con mayor costo-efectividad fue el tratamiento con alendronato de 10 mg, medicamento de administración diaria por vía oral, para el cual se obtuvo un costo de $188,482.40 USD, una tasa de efectividad de 55% y un coeficiente de efectividad de 0.0343. El tratamiento con denosumab fue el más costoso ($725,625.05 USD) y el menos costo- efectivo (Coeficiente C-E 0.1814), mientras que el ácido zoledrónico tuvo un costo de $377,291.92 USD y un coeficiente C-E de 0.0920.  Conclusiones: El alendronato es el tratamiento de la osteoporosis más costo-efectivo para la prevención de fracturas de cadera en mujeres postmenopáusicas, por lo cual debería recomendarse como primera opción en estas pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To identify the most cost-effective treatment for osteoporosis in the prevention of hip fractures in postmenopausal Mexican women without social security in the first level of care.  Material and Methods: A cost-effectiveness analysis was performed for three osteoporosis treatment schemes selected for their different administration routes and dosage. The treatments were estimated for a one-year period. The costs of each intervention were estimated from the provider&#8217;s perspective and the prices from the Mexican market available for July 2021 were considered. Treatment effectiveness was determined from previous studies on the effect of each treatment on the prevention of hip fractures. The cost-effectiveness coefficient was calculated for each treatment.  Results: The most cost-effective treatment was 10 mg alendronate, a daily oral treatment, with a $188,548.61 USD cost, a 55% effectiveness and a 0.0377 cost-effectiveness coefficient. Treatment with denosumab was the most expensive ($725,625.05 USD) and the least effective (C-E coefficient 0.1814), zoledronic acid had a $377,291.92 USD cost and a 0.0920 C-E coefficient.  Conclusions: Alendronate is the most cost-effective treatment of osteoporosis for the prevention of hip fractures in postmenopausal women and should be recommended as the first-line treatment in these patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Costo-efectividad]]></kwd>
<kwd lng="es"><![CDATA[Osteoporosis]]></kwd>
<kwd lng="es"><![CDATA[Posmenopausia]]></kwd>
<kwd lng="es"><![CDATA[Alendronato]]></kwd>
<kwd lng="es"><![CDATA[Primer nivel de atención]]></kwd>
<kwd lng="en"><![CDATA[Cost-effectiveness]]></kwd>
<kwd lng="en"><![CDATA[Osteoporosis]]></kwd>
<kwd lng="en"><![CDATA[Postmenopause]]></kwd>
<kwd lng="en"><![CDATA[Alendronate]]></kwd>
<kwd lng="en"><![CDATA[Primary health care]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy</collab>
<article-title xml:lang=""><![CDATA[Osteoporosis Prevention, Diagnosis, and Therapy]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2001</year>
<volume>285</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>785-95</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eastell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Neill]]></surname>
<given-names><![CDATA[TW]]></given-names>
</name>
<name>
<surname><![CDATA[Hofbauer]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Langdahl]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Reid]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Gold]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postmenopausal osteoporosis]]></article-title>
<source><![CDATA[Nat Rev Dis Prim]]></source>
<year>2016</year>
<volume>2</volume>
<page-range>1-17</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindsay]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cosman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteoporosis]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Kasper]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Fauci]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Hauser]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<source><![CDATA[Harrison, Principios de Medicina Interna]]></source>
<year>2016</year>
<volume>2</volume>
<edition>19</edition>
<page-range>2488-504</page-range><publisher-name><![CDATA[McGraw-Hill Interamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía de Práctica Clínica. Diagnóstico y Tratamiento de Osteoporosis en el Adulto]]></source>
<year>2013</year>
<publisher-name><![CDATA[Inst Mex del Seguro Soc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reza-Albarrán]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteoporosis]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2016</year>
<volume>152</volume>
<page-range>84-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>OMS</collab>
<source><![CDATA[Envejecimiento y salud]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>Asamblea Mundial de la Salud</collab>
<source><![CDATA[Informe sobre los resultados de la OMS: presupuesto por programas 2016- 2017]]></source>
<year>2018</year>
<month>&#</month>
<day>82</day>
<publisher-name><![CDATA[Organización Mundial de la Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calixto]]></surname>
<given-names><![CDATA[ARJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[PLV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impacto de la osteoporosis en el desarrollo social]]></article-title>
<source><![CDATA[Rev Cuba Med Gen Integr]]></source>
<year>2010</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>694-705</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Antolín-López]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-Herrea]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez-Hurtado]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Ríos-Mejía]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Garnica-Cuellar]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera-Landero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía de Práctica Clínica. Diagnóstico y Tratamiento de Osteoporosis en mujeres posmenopáusicas]]></source>
<year>2018</year>
<publisher-name><![CDATA[Inst Mex del Seguro Soc]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Brien]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stoddart]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Torrance]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis coste-efectividad]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Drummond]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Brien]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stoddart]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Torrance]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
</person-group>
<source><![CDATA[Métodos para la evaluación económica de los programas de asistencia sanitaria]]></source>
<year>2001</year>
<edition>Segunda</edition>
<page-range>109-56</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ediciones Díaz de Santos, S. A]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<collab>SEGOB</collab>
<source><![CDATA[Cubos dinámicos]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<collab>INEGI</collab>
<source><![CDATA[Población total según condición de derechohabiencia]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-Arellano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Milla-Villeda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Vera]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cisneros-Pérez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lazalde]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de osteoporosis y osteopenia en mujeres oriundas de la ciudad de Durango, México, de 50 y más años de edad diagnosticadas por DEXA en antebrazo]]></article-title>
<source><![CDATA[Gac Méd Méx]]></source>
<year>2007</year>
<volume>143</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>365-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shamah]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
<name>
<surname><![CDATA[Cuevas]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Gaona]]></surname>
<given-names><![CDATA[PEB]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[ALM]]></given-names>
</name>
<name>
<surname><![CDATA[Mendoza]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<source><![CDATA[Encuesta Nacional de Salud y Nutrición 2018-19. Resultados Nacionales]]></source>
<year>2020</year>
<page-range>268</page-range><publisher-name><![CDATA[Instituto Nacional de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McClung]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Denosumab for the treatment of osteoporosis]]></article-title>
<source><![CDATA[Osteoporos Sarcopenia]]></source>
<year>2017</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>8-17</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sosa-Henríquez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Groba-Marco]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-González]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El ácido zoledrónico en el tratamiento de la osteoporosis]]></article-title>
<source><![CDATA[Rev Osteoporos Metab Min]]></source>
<year>2010</year>
<volume>2</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>S21-30</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iwamoto]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Takeda]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Matsumoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: A review of the literature]]></article-title>
<source><![CDATA[Clin Interv Aging]]></source>
<year>2008</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>483-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maciel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tamayo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Direct costs of osteoporosis and hip fracture: An analysis for the Mexican Social Insurance Health Care System]]></article-title>
<source><![CDATA[Salud Publica Mex]]></source>
<year>2009</year>
<page-range>S108-13</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
